Revive Therapeutics Provides Update on Phase 3 Clinical Trial for Bucillamine in COVID-19
TORONTO, April 11, 2022 (GLOBE NEWSWIRE) -- Revive Therapeutics Ltd. (“Revive” or the “Company”) (OTCQB: RVVTF) (CSE: RVV) (FRANKFURT:31R), a specialty life...
Report on Mitesco (MITI): Zacks Issues $0.53 Price Target, a 165% Potential Gain.
LIVE QUOTE
Original Report: Initiating Coverage...
Citius Pharmaceuticals Reports Topline Data from the Pivotal Phase 3 Study of Cancer Immunotherapy.
Citius Pharmaceuticals Reports Topline Data from the Pivotal Phase 3 Study of Cancer Immunotherapy I/ONTAK (E7777) for the Treatment of Persistent or...
Surna Cultivation Technologies Signs Contract for New Addition to Product Portfolio
Converted Air Sanitization Product Partnership to Customer Contract in Under Thirty Days
Louisville, Colorado, April 05, 2022 (GLOBE NEWSWIRE) -- CEA Industries...
Video: China’s Evergrande. The $300 Billion Unwind has Started. Lehman Bros., Part Deux?
Right up there with Invasion, Inflation and Interest Rates..is China's Evergrande.
China Property developer Evergrande missed its first...
Adding Smart for Life (SMFL) $0.85 to the Watch List.
Adding another "Broken" IPO to the Watch List.
We're not sure if "broken" is the appropriate description, when...
Report: First Vaccines, then Antivirals. Will the Anti-Inflammatory Be the Next Success Story in...
New Report on Revive Therapeutics (RVVTF, RVV). Ushering in Advances in Anti-Inflammatory and Antioxidant Drugs, as a Tool Against Covid.
Glutathione: The “Mother” of all Antioxidants…
Glutathione, also known as GSH, is a molecule found naturally in your body. It is produced by the liver and nerve cells...
Revive Therapeutics (RVVTF) Regulatory Update Archive.
April 12th, 2022 update. Discusses potentially halting the Study early due to positive efficacy based on other clinical outcomes evaluated such as...
Stand Down. “A Super Bubble” says Jeremy Grantham, the “Day of Reckoning is Here”...
Calling a Super Bubble. | Front Row with Jeremy Grantham
https://youtu.be/JlEGU2ypr1Q
Latest article
Adding Citius Pharma (CTXR) $0.66 to 2024 Watch List.
Three Years Since we Last Added Citius (CTXR) to the Watch List, and it Looks Better Than Ever!
Citius Pharmaceuticals (CTXR) Prospectus, Powerpoint & Fact Sheet.
CRANFORD, N.J., April 26, 2024 /PRNewswire/ -- Citius Pharmaceuticals Inc. (Nasdaq: CTXR) ("Citius" or the "Company"), a late-stage biopharmaceutical company dedicated to the development and commercialization...
GeoVax (GOVX) Launches Vaccine Manufacturing System.
GeoVax Achieves Milestone in Transition to Commercially Validated Manufacturing System
Manufacturing Process for Phase 3 and Commercial Production...
